No Data
ALS Therapy Market Seen Increasing to Nearly $1.3B by 2029
Five-year Data for Genentech's Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk
- After 5 years of treatment, 91% of children were alive — without treatment, children with Type 1 SMA would not be expected to live past 2 years of age -- 96% of Evrysdi-treated children could swallo
Global Ferroptosis Targeting Therapy Market Opportunity & Clinical Trials Insight 2024, Featuring Kojin Therapeutics, MitoImmune Therapeutics, Prothegen, PTC Therapeutics, Sumitomo and Tharimmune - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global Ferroptosis Targeting Therapy Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.The panorama of scienti
William Blair Maintains PTC Therapeutics(PTCT.US) With Buy Rating
William Blair analyst Sami Corwin maintains $PTC Therapeutics(PTCT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.9% and a total average return of 3.7% over th
Express News | EMA Says Chmp Has Restarted Evaluation of an Application to Renew Conditional Marketing Authorisation for Translarna (Ataluren)
PTC Therapeutics to Participate at Upcoming Investor Conference
WARREN, N.J., May 29, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference: William Blair's 44th Ann
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.